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THE IMPACT OF CURRENT POLICY AND
REGULATION ON FUTURE STEM CELL
HUMAN HEAL TH APPLICATIONS
MICHAEL J. MALINOWSKI*
INTRODUCTION

My approach to bioethics is very much application centered, meaning
in part that I prioritize reality and ongoing human experiences -the impact
on lives in motion today-over theory, with appreciation that the two often
work well together. 1 I use theory to assist in problem identification and
analysis, but I favor a fact-based approach driven by what people are
2
actually living through today. While doing so, I also try to be thoughtful
and think longer term and proactively.
I believe that those of us who invest our professional lives in bioethics
and health policy have an obligation to be professionally self-aware and
open. We must figure out what drives our thinking and why, identify where
we stand on particular issues and why, and then disclose that information
honestly when we enter debates. Otherwise, meaningful communication

*

Ernest R. and Iris M. Eldred Professor of Law and Associate Director, Program in
Law, Science, and Public Health, Paul M. Hebert Law Center, Louisiana State
University. The presentation for this live symposium on November 19, 2004 was
derived from another given by the author on October 11, 2004 at National Academies,
Workshop on Guidelines for Human Embryonic Stem Cell Research (Oct. 11-12,
2004, Washington, D.C.). The author would like to thank Professor R. Alta Charo for

I.

interactions in conjunction with the Workshop that contributed to this effort, Professor
Nanette Elster for her thoughtful suggestion, and Daven Williams for her research
assistance.
See Michael J. Malinowski, Law, Policy,

and Market Implications of Genetic

Profiling in Drug Development, Hous. J. HEALTH LAW & PoL'Y 31, 59-61 (2002).

2.

"One might argue, therefore, that there is a moral imperative in addition to a
professional obligation to bridge law and policy with meaningful fieldwork.... in both
life science R&D and health care delivery ...." Id at 61.
See generally id.
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and dialogue are unlikely. Even if more often than not we end up agreeing
that we disagree because our personal determinants on an issue are not
aligned, we can do so with a baseline of communication and understanding,
and relay the same to others in the debate.
Given

this

approach,

today's

topic

certainly

necessitates

some

disclosure by me at the outset. Therefore, I will begin by explaining my
on human embryonic stem cell research

position

(hESCR)

and my

underlying rationale for my position. In Part II of this presentation, I will
address the impact of current federal policy and regulation on hESCR in
the context of ongoing basic research. In Part III, I will discuss the potential
impact

of existing federal

policy

and regulations on

human

health

applications of hESCR. I will conclude in Part IV by sharing my overriding
thoughts about the regulatory environment for hESCR in the United States.
Given the chronic commingling of therapeutic and reproductive cloning
since the late 1990s, I believe that assurance to quell discomfort with the
notion of human cloning for reproduction is a prerequisite for significantly
increasing support for hESCR in the near future. As I will explain, I believe
that such assurance is possible only through more meaningful regulatory
oversight and accountability in the field of assisted reproduction (AR) in
the United States.
I. OVERALL POSITION ON HESCR
My position on hESCR is influenced heavily by the state of AR in the
United States, and I believe that these issues are fundamentally entangled.
AR has become a burgeoning, multibillion-dollar industry annually in this
3
country, and one that is growing exponentially. Professor George Annas

has done a wonderful job--in literature, in presentations, and in the popular
media, including a PBS documentary entitled Making Babies that I have
4
shown often in my classes -drawing attention to the dearth of U.S. federal
regulation in the field of AR. 5 Professor Annas has referred to AR in the

3.

See Michael J. Malinowski, Choosing the Genetic Makeup of Children: Our Eugenics

Past-Present, and Future?, 36 CONN. L. REv. 125, 179-97 (2003) (fully explaining
the present state of regulation of AR in the

U.S., including dependence upon

voluntary reporting, and the market, social, and scientific factors driving extensive
expansion of use of AR technologies). Cf PRESIDENT'S COUNCIL ON BIOETHICS,

REPRODUCTION AND RESPONSIBILITY: THE REGULATION OF NEW BIOTECHNOLOGIES

54-63

(2004),

available

at

http://www.bioethics.gov/reports/reproductionand

responsibility/_pcbe final_reproduction_and_responsibility. pdf
_

[hereinafter

PRESIDENT S COUNCIL, REPRODUCTION AND RESPONSIBILITY]. According to one
'

report, AR constituted a $4 billion industry annually as of 2001. See id. at 191.
4.
5.

Frontline: Making Babies (PBS television broadcast, June 1, 1999).
See generally George J. Annas, The ABCs of Global Governance of Embryonic Stem

Cell Research: Arbitrage, Bioethics and Cloning, 39 NEW ENG . L. REV. 489 (2005).
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United States as "the wild West"6 of American medicine, and that pretty
. 7
much captures 1t.
The consequential reality is that we know, according to data released
by the American Society for Reproductive Medicine (ASRM) on May 7,
2003, that we have more than 400,000 frozen embryos left over from AR
procedures and derogated to what I will call "cryopreservation purgatory."8
These numbers are probably very low because they are based on self
reporting,9 and AR has been burgeoning since 2003. Reality is that these
embryos are the creation of medical intervention and their continued
existence is wholly dependent upon the same. As we heard this morning
from Dr. Suzanne Kadereit, 10 Harvard's Boston Children's Hospital is not
going to pay to keep the embryos perpetuating forever, and we should not
anticipate more from its sister institutions.
For the purposes of argument, let us elevate the existence of these
frozen embryos to a status much higher than what they actually are. Let us
equate them with people with life histories who are dependent on medical
intervention for their continued existence-for example, an eighteen-year
old who suffered severe brain trauma in an automobile accident or an
eighty-six-year old with very advanced Alzheimer's. It is basic, well
See, e.g., Rosario M. Isasi & George J. Annas, Arbitrage, Bioethics, and Cloning: The
ABCs of Gestating A United Nations Cloning Convention, 35 CASE W. RES. J. INT'L L.
6.
7.
8.

397 (2003).
See Isasi & Annas, supra note 5, at 397.
See Malinowski, supra note 3, at 180-89.
Id. at 130 n.11 (citing American Society for Reproductive Medicine, Vast Majority of
Cryopreserved Embryos Slated for Future Family Building, ASRM BULL., May 7,

9.

2003, available at http://www.asrm.org/Washington/Bulletins/vol5no30.html).
The United States relies heavily upon voluntary reporting by those practicing AR.
The

Centers

for

Disease

Control

and

Prevention

(CDC)

has

contracted

implementation of the Fertility Clinic Success Rate and Certification Act of 1992,
Pub. L. 102-493, 106 Stat. 3146 (1992), to the Society for Assisted Reproductive
Technology (SART), which is part of the American Society for Reproductive
Medicine (ASRM). Malinowski, supra note 3, at 182. The CDC compiles submitted
data and publishes reports. See, e.g., CTRS. FOR DISEASE CONTROL & PREVENTION,

2000 Assisted Reproductive Technology Report, available at http://www.cdc.gov/
reproductivehealth/ARTOO/download.htm

(Dec.

20,

2002);

CTRS.

FOR DIS EASE

CONTROL & PREVENTION, 2001 Assisted Reproductive Technology Success Rates,
available
10.

at

http://www.cdc.gov/reproductivehealth/ARTO 1/download.htm

(Dec.

2003).
Suzanne Kadereit & Pamela J. Hines, An Overview of Stem Cell Research, 39 NEW
ENG. L. REV. 607 (2005). But see Miller v. Am. Infertility Group, No. 02-L-7394 (Cir.

Ct. Cook County, Ill., County Dep't Law Div., Feb. 4, 2005) (memorandum opinion
and order) (on file with author) (holding that a couple whose frozen embryos were
accidentally destroyed at a fertility clinic has the right to file a wrongful death
lawsuit).
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established law and policy in the United States and in many other
industrialized countries that, when a person is incompetent and wholly
dependent upon medical intervention for his or her continued existen ce,
.
and that person has not expressed wishes to the contrary before becommg
incompetent, the family or guardian of that person has the right to make
decisions about withdrawing medical intervention. 1 1 Often, the decision to
withdraw treatment is accompanied by a decision to donate the person's
physical existence for use in organ transplantation or research to benefit
2
others. 1
When the life lost is a frozen embryo rather than an incompetent
person, however, President Bush's policy on stem cell research greatly
impedes the ability of "family members" to mitigate the loss of life by
making potentially significant health contributions. Under the Bush policy,
the option to donate cryopreserved embryos is limited to research with
private money and removed from academic institutions, which
understandably makes that option much less appealing to many people.13
The policy also creates a significant disincentive and, at the least, major
administrative transaction costs for the thousands of academic institutions
and researchers who receive some of the many billions of taxpayer dollars

11.

BARRY R. FURROW E T AL., HEALTH LAW: CASES, MATERIALS AND PROBLEMS 13791446 (5th ed. 2004); TIMOTHY STOLTZFUS JOST, READINGS I N COMPARATIVE HEALTH

LAW & BIOETHICS 299-326 (Carolina Academic Press 2001) (discussing the right to

die).
12.

See FURROW ET AL., supra note 11, at 1315-43. Cf UNIF. DETERMINATION OF DEATH
ACT § 1, 12A U.L.A. 593 (1980). The act has been expanded to encompass "brain
death" in the definition of death and, generally, to make it easier to donate organs for
transplantation. FURROW ET AL., supra note 11, at 1321.

13.

Fact Sheet, The White House, Embryonic Stem Cell Research (Aug. 9, 2001),
available at http://www. whitehouse.gov/news/releases/2001/08/20010809-1.html. On
August 9, 2001, President Bush declared federally funded research permissible on
hESCs already extracted from embryos at that time. Id.; see also Address to the

Nation on Stem Cell Research, 2 PUB. PAPERS 953 (Aug. 9, 2001), available at
http://www.whitehouse.gov/news/releases/2001108/20010809-2.html.
after,
Soon
access to and the quality of these lines were called into question. See, e.g., Sheryl Gay
Stolberg, Ruling by US. Widens Study of Stem Cells, N.Y. TIMES, Aug. 7, 2002, at
A l . Recently, these lines have been declared probably useless for human medicinal

applications because they were created with mouse feeder cells a reflection of the
state of science at that time, and many are of poor quality. See
aren Kaplan, Study
Says All Stem Cell Lines Tainted, L.A. TIMES, Jan. 24, 2005, at Al. This
issue also
was raised and discussed several times at a public workshop
held at the National
Academy of Sciences on October 11-12, 2004 in Washing
ton D.C. See

K

generall_v

NAT'L ACAD. OF Sc1s., Guidelines for Human Embryon
ic Stem Cell Research: A
Public Workshop, at http://dels.nas.edu/bls/stemcell.ht ml
(last visited Feb. 15, 2005)
[hereinafter NAT'L AcAD. OF Sers., Public Workshop].
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the federal government invests in biomedical research each year. 14 This
policy also contributes to the decision reached by the many thousands of
people who have received AR services and who do not want biological
offspring beyond their own families to simply make no decision or an
affinnative decision to allow the cryopreservation of their leftover embryos
to linger on-perhaps at the discretion of an AR clinic.15 Consequently, the
numbers of embryos derogated to cryopreservation with no chance of
implantation for reproduction should rise in the United States in
conjunction with advancement and use of AR services. 16
President Bush has stated repeatedly that his policy on human
embryonic stem cell research is rooted deeply in respect for embryos and
human life, 17 and the same is said by Leon Kass who chairs the President's
Council on Bioethics and is reflected in the Council's position.18 It seems
terribly inconsistent to me to be creating embryos without foresight about
their fate, without any meaningful and direct government oversight, and
placing them in cryopreservation purgatory for extended periods of time

14.

The National Institutes of Health (NIH) alone was a conduit for a federal budget of
$28 billion in 2004, and NIH's budget for 2005 is $28.6 billion. Jonathan Weisman,

2006 Cuts in Domestic Spending on Table, W ASH. POST, May 27, 2004, at Al; Drug
Development: Medicine Price Hike Highlights Controversy of Government Funding
Drug Research, MED. LETTER ON CDC & FDA, June 20, 2004, available at 2004 WL
15.

55170701.
See supra note 10 and accompanying text (comments of Dr. Kadereit). Resistance to
putting one's embryos up for donation in this context is not surprising, for many seek
AR services rather than adoption because of the value they place on biological ties to
offspring. For case studies that illustrate this point, see 18 Ways to Make a Baby (PBS

16.

television broadcast, Oct. 9, 2001). See also Miller, No. 02-L-7394.

Expanding use of AR services in the United States is driven by many influences,
including demographic and cultural trends resulting in delays in reproduction and

acceptance of AR, the number of AR service providers and their marketing efforts,
the profitability of providing AR services, and increasing scientific capabilities,
including preimplantation genetic diagnosis (PGD) that allows genetic selection
among available embryos before implantation. See generally Malinowski, supra note
3; John A. Robertson, Extending Preimplantation Genetic Diagnosis: The Ethical
17.

Debate, 18 HUM. REPROD. 465 (2003).
Heather L. Fowler, Misapplied Ethical Considerations: U.S. Federal Stem Cell
Mandates lack Global Focus and Market Foresight, 36 CORNELL INT'L L.J. 521, 534
(2004); Tommy G. Thompson, Why Bush's Stem Cell Policy is Reasoned-and Why
it's

18.

Working,

USA

TODAY,

Aug.

16,

2004,

at

llA,

available

at

http://www.usatoday.com/news/opinion/editorials/2004-08-15-stem-cells_x.htm. See
generally supra note 13.
See LEON R. KASS, LIFE, LIBERTY AND THE DEFENSE OF DIGNITY: THE CHALLENGE FOR
BIOETHICS 130 (Encounter Books 2002). For the Council's position on this issue and

others, see http://www.bioethics.gov. See also PRESIDENT'S COUNCIL, REPRODUCTION

AND RESPONSIBILITY, supra note 3.
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without any intention of using them when there are potential medical
benefits to existing living, breathing people. The Bush Administration and
supporters of his policy question this potential and suggest alternatives to
19
Doing so necessitates speculation in the negative about the

hESCR.

outcome of ongoing and future scientific research with hESCs, which is a
mirror reflection of the Administration's major criticism of advocates for
hESCR-that they are speculating (in the positive) when they identify
20
potential clinical applications. The fact is that the vast majority of Nobel
Laureates in science recognize human health potential in hESCR and
21
support U.S. federal funding of it.
Presumably, the visionaries excited
about hESCR are hyping the potential clinical use, but the funny thing
about science is that you never really know unless you try.

I have seen

accomplishments in science during the last decade, including completion of
a map of the human genome ahead of schedule and under budget, that

I was

told by many top medical and science people in the early 1990s would not
22
happen. The division between the pragmatists in medicine and visionaries
23
in science now has shifted beyond mapping the human genome to making
medical sense out of it, and we are all debating how quickly that will come.

II.

ONGOING BIOMEDICAL RE SEARCH AND DEVE LOPMENT (R&D)

My position on hESCR now established, let us sketch a regulatory
picture for the future development of stem cells in application-and do that
with some cautious skepticism about how quickly these applications are
going to come. When

I contemplate applications,

I do not view the future

19.

Research with adult stem cells is frequently pointed to as an alternative that is
showing more scientific advancement. For example, President Bush has and continues
to make this argument. See, e.g., Address to the Nation on Stem Cell Research, supra
note 13. See generally infra note 21.

20.

Associated Press, First Lady Joins Stem Cell Debate (Aug. 9, 2004), available at
http://www.cbsnews.com/stories/2004/07/28/politics/printable632432.shtml.

21.

Letter from Nobel Laureates to President Bush (Feb. 21, 2001), available at
http://www.washingtonpost.com/ ac2/wp-dyn/A37117-200 1 F eb21? language=prin ter.
See generally COMMITTEE ON THE BIOLOGICAL AND BIOMEDICAL APPLICATIONS OF

STEM CELL RESEARCH, STEM CELLS AND THE FUTURE OF REGENERATIVE MEDICINE
(Nat'l Acad. Press 2002) (discussing stem cell research and its potential to improve
human health); ANN B. PARSON, THE PROTEUS EFFECT: STEM CELLS AND THEIR
PROMISE FOR MEDICINE (Joseph Henry Press 2004). See also Harvey Fineberg,
Remarks at the National Academy of Sciences Public Workshop (Oct. 12, 2004)
(transcript on file with author); NAT'L ACAD. OF Sers., Public Workshop, supra note
13.

22.

Michael J. Malinowski, Separating Predictive Genetic Testing from Snake Oil:
Regulation, Liabilities, and Lost Opportunities, 41 JURIMETRICS J. 23, 26 (2000).

23.

Id. at 24 n.3, 25 n.4 and accompanying text.
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from only a clinical delivery standpoint. Rather, my perspective, shaped by
years of law practice and other commercial sector experience, is very much
from the laboratory bench to market. Many important commercial
applications are research tools to enable other basic research in human
health and corollary applications.24
The timing of jolting, fundamental advancements in hESCR during
the late 1990s has been politically problematic for the field. The isolation
of human stem cells regorted in 1998 by Geron Corporation and the
University of Wisconsin 5 came almost literally on the tail of Dolly-the
first successfully cloned mammal. 26 Dolly triggered an immediate reaction
of fear of cloning for human reproduction, and human cloning and
reproduction have been extensively commingled in the popular press,
public mindset, and legislative activity ever since. 27 This cloning override
between therapy and reproduction is not entirely unfair because, in fact, the
science does carry over. If one develops techniques such as somatic cell
nuclear transfer28 to engage in hESCR for patient-tailored medicinal
applications, presumably those could be used in AR. In fact, the technique
was developed in the process of cloning mammals for reproduction
Dolly. The human reproduction concern "has legs" from a pragmatic point
of view because the U.S. federal government does not regulate AR in a
comprehensive, direct manner.29 At the very least, drawing this connection

24.

Consider the myriad compounds that have been patented and, through licenses and
commercial royalty arrangements, used in diverse clinical applications. See generally
BOSTON CONSULTING GROUP, THE PHARMACEUTICAL INDUSTRY INTO ITS SECOND
CENTIJRY: FROM SERENDIPITY TO STRATEGY 38-39 (Jan. 1999).

25.

Terry Devitt, Wisconsin Scientists Culture Elusive Embryonic Stem Cells (Nov. 5,

26.

For more information, visit the web site of the Roslin Institute in Edinburgh,

1998), at http://www.news.wisc.edu/3327html.
Scotland, where Dolly was created, at http://www.roslin.ac.uk/public/cloning.html.
See also Dolly the Sheep, in WIKIPEDIA ENCYCLOPEDIA, at http://en.wikipedia.org/

27.

wiki/Dolly_the_sheep (last modified Feb. 2, 2005).
See Paul Lesko & Kevin Buckley, Attack of the Clones ... and the Issues of Clones, 3
COLUM.

Ser.

&

TECH.

L.

REV.

1

(2002),

at

http://www.stlr.org/cite.cgi?

volume=3&article=3; Meredith Lewis, Book Note, Age of Human Cloning and the
Constitutional Crisis that May Result, 6 J.L. & FAM. STUD. 171 (2004); Shawn E.
Peterson, Note, A Comprehensive National Policy to Stop Human Cloning: An
Analysis of the Human Cloning Prohibition Act of 2001 with Recommendations for
Federal and State Legislatures, 17 NOTRE DAME J.L. ETHJCS & PUB. POL'Y 217, 21718 (2003).
28.

STEM CELL NETWORK,

What

is

Somatic

Cell Nuclear

Transfer

{SCNT)?,

at

http://www.stemcellnetwork.ca/guide/focus.php?=id=l 74 (last visited Feb. 10, 2005);

see COMMITTEE ON THE BIOLOGICAL AND BIOMEDICAL APPLICATIONS OF STEM CELL
29.

RESEARCH, supra note 21, at 10-12.

See supra notes 4-7 and accompanying text; see also infra notes 73-76 and
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is not unreasonable, illogical, irrational or unfair. Similarly, baseline moral
and religious objections to destroying embryos stirs the issues of cloning
for therapy and cloning for reproduction into each other.
Even with the reelection of President Bush and absent a change in
federal policy on hESCR, it is certain that hESCR is going to continue. The
research will move forward primarily as a private market endeavor. In fact,
NIH is encouraging this by grant funding efforts to make cell lines
30
available for private research and development.
On a personal note, as a
taxpayer and as one who has spent the vast majority of his career practicing
law and engaging in scholarship in the area of technology transfer and
development in biotechnology, I find the Administration's position to be
hypocritical and generally troubling. It is no consolation to me to hear that
the Administration's position on hESCR is tempered by the fact that NIH,
in addition to putting up
also putting up

$2 5 million for direct support of this research, is

$25 million to deal with the transaction cost of complying

with its own restrictive policy on federal funding.

31

Rather, it seems

awfully hypocritical to me to put so much government money allegedly
committed to research into lowering transaction costs created because the
Bush Administration does not want to support that research in an open
way-though implicitly the Administration acknowledges the importance
32
of hESCR enough to grant fund efforts to "Coase around" its own policy.
Even without NIH funding to bridge transaction costs created by
President Bush's policy, the biomedical establishment that is dependent
upon federal funding is committed to doing this research, and is going to
find a way to do some of it-there is no question. We are seeing that
happen now. Notably, there are few instances where major universities
34
33
Harvard and Stanford -have shadowed the arrangement between Geron

accompanying text. See generally Malinowski, supra note 3.

30.

0. Carter Snead, Keynote Address: Preparing the Groundwork for a Responsible

Debate on Stem Cell Research and Human Cloning, 39 NEW ENG. L. REV. 479
(2005).
31.

See id A similar message was issued by a James Battey, Director, National Institute
on Deafuess and Other Communication Disorders, on October 12, 2004 at Guidelines

for Human Embryonic Stem Cell Research, a workshop organized and hosted by the
National Academy of Sciences, October 12-13, 2004, Washington, D.C.,

in which the

author participated.

32.
33.

See generally Ronald Coase, The Problem of Social Cost, 3 J.L. & ECON. I (1960).
Harvard's effort is the Harvard Stem Cell Institute, which announced

in March 2004

that it had developed seventeen new embryonic stem cell lines. See Harvard Stem

Cell Institute, HARV. GAZETTE, Apr. 22, 2004, available at http://www.news.
harvard.edu/gazette/2004/04.22/science.html.
34.

�

tanford has established the Institute for Cancer/Stem Cell Biology and
.
mformatlon about which is available at http://med.stanford.edu/institutes/.

Medicine,
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and the University of Wisconsin that produced the 1998 fundamental
35
hESCR advances. These universities have put up administrative divisions
36
and created separate entities to engage in hESCR without federal funding.
The problem is that there are not too many schools in the position of
Harvard and Stanford. I teach at Louisiana State University, a good school
with some A-level science through the Pennington Biomedical Research
Center, AgCenter, School of Veterinary Medicine, Health Sciences Center,
and so forth, but LSU is not positioned financially or politically to create a
quasi-private entity for hESCR. Even with state support, doing so would be
extremely difficult, though LSU does receive a significant amount of
federal funding to support research projects throughout the LSU System.
LSU is representative of a considerable portion of the research university
community, and mechanisms created by a few of the most renowned
private institutions, even if successful and duplicated, are unlikely to offset
the loss of meaningful access to tens of billions of dollars in federal
funding annually for an entire field of science.
In conjunction with private universities, a few states are getting
directly involved in hESCR. Most notably, California has committed $3
37
billion over ten years. Without putting u the same billions of dollars,
New Jersey too has taken a positive stand.

�

8

Nevertheless, other states as

diverse as Massachusetts and Louisiana have either seen supportive
legislative initiatives fail or actually considered legislative proposals to
39
move in the opposite direction. Moreover, California's financial support

35.

For information about this arrangement, visit the site of the Wisconsin Alumni
Research Foundation, at http://www.warf.ws, which holds composition of matter

36.

37.

patents in stem cell lines-a potential basis for property claims to all stem cell lines.
See supra notes 31-32 and accompanying text.

$3 Billion on
TIMES, Sept. 20, 2004, at A l; Dan Vergano, Embryonic
Imbroglio, USA TODAY, Oct. 27, 2004, at D6.

John M. Broder & Andrew Pollack, Californians to Vote on Spending
Stem Cell Research, N.Y.

38.

Wesley Chang, Comment, Arrested Development: Patent Laws, Embryonic Stem Cell
Research, and the Organ Black Market,

39.

IO Sw. J.L. & TRADE AM. 407, 424-25

(2004).
Louisiana already recognizes the embryo as a juridical person. LA. REV.

STAT. ANN.
§§ 121-33 (West 2004). A legislative proposal to ban human cloning that would have

effectively prohibited hESCR research in the state regardless of the source of funding
was circulated in

2004. See H.R. 803, 2004 Sess. (La. 2004). Massachusetts, though

in a heated biotech race with California, was unable to enact proposed legislation
supporting stem cell research. However, Thomas M. Finneran, the former Speaker of
the House, who opposed that legislation, is now supportive in his role as Chief
Executive

Officer

of the

Massachusetts

Zimmerman, An Odd Job for Tom Finneran,

Biotechnology

Council.

See

Mark

BOSTON GLOBE, Oct. 3, 2004, at DJ 0

(letter to the editor); Scott S. Greenberger & Frank Phillips, Stem Cell Bill Tops
Agenda as Legislature Convenes,

BOSTON GLOBE, Jan. 6, 2005, at Al; John
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cannot offset the tens of billions of dollars NIH invests annually in
biomedical research and the associated, potentially enormous opportunity
cost.40 As we witnessed through the Human Genome Project, meaningful
support from the U.S. government in areas o f research can have a
distinctive effect in terms of establishing prioritization, "critical mass"
participation, and focus throughout the global science community.
III. FUTURE HUMAN HEALTH APPLICATIONS

So what is the opportunity cost in terms of human health
applications? Throughout this symposium,41 the NAS's forum last month,42
and the scientific and popular literature,43 many potential human health
applications of ongoing hESCR have been identified. Some of the more
dramatic applications are a cure for diabetes, effective treatment for
Alzheimer's, and spinal cord repair.44 President Bush's policy of restricted
funding for hESCR is premised on the assumption that the applications of
the technology are years in the future. However, there are immediate and
certain applications of hESCR that refute this assertion. Deeper knowledge
about cell differentiation could have a profound impact on basic biomedical
research. Consider creation of cell lines free of non-human animal cultures,
an abundance of cell lines tailored to genetic characteristics of specific
disease populations, novel vectors, and other biomaterials which, through
material transfer and development agreements, become valuable tools used
in many areas of biomedical research. If human experience in biomedical
R&D is any indication, incremental clinical applications in the process of
moving from the present towards effective therapies are actually probable
with meaningful investment in hESCR. For example, consider use of cell
manipulation techniques to conduct much more precise toxicity testing
perhaps to better isolate adverse events associated with pharmaceuticals

Finneran Now Backs Stem Cell, BOSTON HERALD, Nov. 10, 2004, at 42.
See supra note 14 and accompanying text (noting that the NIH has a budget of $28.6
billion in 2005).
Strahinich,

40.

42.

See generally Symposium, Stem Cell Research to Human Cloning:
Draw the Line?, 39 NEW ENG. L. R.Ev. 477, 477-714 (2005).
See NAT'L ACAD OF Sc1s. Public Workshop, supra note 13.

43.

See, e.g.,

41.

Do

We

.

COMMITTEE ON THE BIOLOGICAL

CELL RESEARCH,

44.

W'here

supra note 21;

AND BIOMEDICAL APPLICATIONS OF STEM

pA RSON, supra note 21.

Research endeavors for human health applications include muscular dystrophy,
autoimmune disorders (lupus, multiple sclerosis, and deafness), cells for drug testing,
replacement salivary gland cells for patients treated with radiation for cancers of the
head and neck, teeth regeneration, infertility, baldness, depression, neurogenesis,
fortification of heart muscle, immune system tolerance for organ transplant patients,
bone r generation, breast reconstr uction, Parkinson's disease, making organs and
�
other b10-structures, spinal cord injury, and aging. PARSON, supra note 21, at 2 l 9-32.
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already on the market and commonly used:
Take the example of a Geron team's having turned human ES
[embryonic stem] cells into what it believes are hepatocytes, the
liver's primary specialized cell. If hepatocytes could be mass
produced from ES cells, drugmakers, who must show that a new
drug has no adverse effects on the liver, would have vast
quantities of liver cells. Currently, a chief source of liver cells for
drug tests are cadavers.

45

As this example suggests, cellular differentiation techniques might
help to modify or at least make better choices among a range of existing
treatments in areas such as oncology. The capability to readily and cost
effectively grow particular kinds of cells may even enable some patient
tailored toxicity testing.
The hESC lines in existence on August 9, 2001-those which may be
used in federally funded research under the Bush Administration's
policy46-were created with exposure to mouse cultures, are limited in their
genetic diversity, generally are of questionable vitality and quality, and in
many instances are encased with proprietary interests. 47 Use of mouse
feeder cells in the creation of these lines, reflective of the state of science at
that time, introduces a muddle of xenotransplantation complications if
48
these lines are to be the basis for human health applications. In January
2005, a study was issued by researchers at the University of California San
Diego and the Salk Institute for Biological Studies in La Jolla, indicating
that the lines probably are too innately contaminated to ever serve as the
49
basis for human health applications.
Assuming we see meaningful human health applications from hESCR
over the next several years in spite of limitations on federal financial
support, are existing regulations and regulatory regimes for human health
products sufficient to handle them? I do believe that the FDA, in
collaboration with sister agencies as necessary under the Coordinated

45.
46.
47.

48 .

Id. at 223.
See supra note 1 3 and accompanying text.
See Malinowski, supra note 3, at 184 n.3 0 1 .
R. Alta Charo, Existing Federal, State and Voluntary Regulation of Embryonic Stem
Cell Research (Oct. 2004), available at http://dels.nas.edu/bls/stemcells/charo.pdf

(distributed at the NAT'L ACAD. OF Sc1s., Public Workshop, supra note 1 3). For more
information about xenotransplantation and related science and regulatory issues, see

CENT. FOR BIOLOGICS EVALUATION & RESEARCH, U.S. FOOD & D RUG ADMIN.,
Xenotransplantation Action
49.

modified June 29, 2004).
See Kaplan, supra note

13.

Plan,

at

http://www .fda.gov/cber/xap/xap.htm

(last
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Framework,50 can rise to the occasion of sufficiently regulating products
developed through hESCR. I say that fully aware tha! we h� ve a ve�y
troubling time in front of us regarding the FDA. I was dtrectly mvolved m
the modernization of the FDA through scholarship and industry
representation.51 A lot of good was done to increase the crossover of new
science into commercial applications. User fees have greatly expanded the
FDA's resources, and also created much more dialogue among the FDA,
industry, and academia. 52 Ultimately, you end up in a world where a very
thick and long-standing wall was taken down between industry and the
government through regulatory reform. While razing this wall arguably
53
accountability
was necessary to fuel the genomics revolution,
mechanisms must be added in its place to ensure some regulatory
checkpoints. 54 The ongoing Cox-2 controversy, coupled with incidents such

50.

51.

52.

53.

Coordinated Framework for Regulation of Biotechnology, 51 Fe d. Reg. 23,302 (June
26, 1986). Under this policy, federal regulatory entities are supposed to collaborate to
regulate biotechnology products and not subject those products to added regulation
just because biotechnology processes are used to make them. See Michael J.
Malinowski, FDA Regulation of Biotechnology Products for Human Use, in
ENCYCLOPEDIA OF ETHICAL, LEGAL AND P OLIC Y ISSUES IN BIOTECHNOLOGY 215
(Thomas H. Murra y & Maxwell J . Mehlman eds., 1999) .
This modernization refers to implementation of the Foo d and Drug Administration
Modernization Act of 1997. Pub. L. No. 105-115, 111 Stat 2296 (codified throughout
21 U.S.C.) [hereinafter FDAMA].
Prescription Drug User Fee Act of 1992, Pub. L. No. 102-571, 106 Stat. 4491
(codified throughout 21 U . S.C.) [hereinafter PDUFA I]. PDUFA I was reauthorized
(PDUFA II) in the context ofFDAMA. Prescription Drug User Fee Act of 1994, Pub .
L. No. 102-571, 106 Stat. 4491 (codified in scattered sections of 21 U. S . C ), renewed
as an addendum to the FDAMA. The FDAMA-renewed the user fee program for five
years and introduced new performance goals and other funda men tal adjustments. See
Malinowski, supra note 50; Prescription Drug User Fee Ammen dments of 2002, Pub.
L. No. 107-188, 116 Stat. 687 (codified throughout 21 U .S.C.) [hereinafter PDUFA
III] (extending the program to Sept. 30, 2007). See generally Fooo & DRUG ADMIN ..
PUDFA III Five-Year Plan, available at http://www.fda.gov/cc/pdufa3/
2003plan/default.html (July 2003).
For support of federal technology transfer policy and practice, see generally NAT'L
INSTS. OF HEALTH , NIH Response to the Conference Report Request for a Plan to
Ensure Taxpayers' Interests are Protected, available at http://www.nih.gov/
news/070101wyden.htm (July 2001); GEN. ACCOUNTING OFFICE, REPORT TO
CONGRES SIONAL COMMITrEES: TECHNOLOGY TRANSFER, A DMINISTRATION OF THE
BAYH-D OLE ACT BY RESEARCH UNIVERSITIES, GAO/RCED-98-126 (May 1998),
available at http://www.gao.gov/archive/l 998/rc98 l 26. pdf [hereinafter GA0
REPORT].

54.

See generally Timothy Caulfield, Globalization, Conflicts of Interests and Clinical
Research: An Overview of Trends and Issues, 8 WIDENER L . SYMP. J. 31 (2001); Janet
Fleetwood, Conflicts of Interest in Clinical Research: Advocating for Patient
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as the alleged failure of Lilly to disclose troubling clinical data for Prozac
which has been on the market for years, may end up being the "thalidomide
55

of 2005" that triggers some major reform.

With that being said, the FDA has been extremely resourceful and
dynamic responding to many scientific and other challenges during the last
decade, and they have made some administrative changes that position
them well to handle hESCR product applications. Most notably, they have
been developing a "tissue products track" and have centered review for all
drugs, including biologics, in the Center for Drug Evaluation and Research
56
(CDER). At least in theory, by centralizing pharmaceuticals in CDER, the
57
Agency opened up the Center for Biologics (CBER) to focus on areas like
hESCR. Unfortunately, as I learned through a conversation at the NAS
58
workshop, the Agency also has gutted a great deal of CBER's resources
and human talent, and that simply has to be corrected.
Now, stepping beyond regulatory oversight, the privatized, extreme
59
commerce approach
President Bush is taking with hESCR will have a
significant impact on how and the extent to which hESCR is applied-both
in biomedical research and in human health markets. Immediate experience

Subjects, 8 WIDENER L. SYMP.

J. 105 (2001); Patricia Kuszler, Curing Conflicts of

Interest in Clinical Research: Impossible Dreams and Harsh Realities, 8 WIDENER L.
SYMP. J. 115 (2001); Michael

J. Malinowski, Academic-Industry Collaborations in
J. ii (2001); Michael J. Malinowski, Institutional

the Clinic, 8 WIDENER L. SYMP.

Conflicts and Responsibilities in Anage of A cademic-Industry Alliances, 8 WIDENER
L. SYMP.

J. 47 (2001); Pilar N. Ossorio, Pills, Bills and Shills: Physician-Researcher's

Conflicts of Interest, 8 WIDENER L. SYMP. J. 75 (2001); Cynthia Robbins-Roth, From
Alchemy to /PO: The Businesses of Biotechnology, 8 WIDENER L. SYMP.

J. 153

(2001); Erica Rose, Financial Conflicts of Interest: How Are We Managing?, 8
WIDENERL. SYMP.

55.

J. l (2001).

Ken Belson, Lilly Shares Fall on Report About Prozac Documents, N.Y. TIMES, Jan.

1, 2005, at C2; Alex Bernson, An Industry in Poor Health, N.Y. TIMES, Dec. 18, 2004,
J. Feder, The Fallout from Celebrex, N.Y. TIMES, Dec. 18, 2004, at

at Al; Barnaby

B l; Gina Kolata, A Widely Used Arthritis Drug is Withdrawn, N.Y. TIMES, Oct. 1,
2004, at Al; Barry Meier, A Top Republican to Ofe
f r Drug Data Bill, N.Y. TIME S ,
Dec. 10, 2004, at C3; Anahad O'Connor & Denise Grady, Problems May Send Many
Patients Back to Good Old Aspirin,

N.Y.

TIMES, Dec. 18, 2004, at Bl. Several major

pharmaceuticals, in an effort to preempt government mandates, are now posting much
more clinical data voluntarily. Meier, supra.
56.

See CENT . FOR DRUG EVALUATION & RESEARCH, U.S. FOOD & DRUG ADMIN., at
http://www.fda.gov/cder (last updated Feb. 18, 2005). See generally Charo, supra

57.

See CENT. FOR BIOLOGICS EVALUATION & RESEARCH , U.S. FOOD & DRUG AoMIN., at
http://www .fda.gov/cber (last updated Feb. 1, 2005).

58.

NAT L ACAD. OF Scis., Public Workshop, supra note 13.

59.

See generally Sean M. O'Connor, Intellectual Property Rights and Stem Cell

note 48.

'

Research: Who Owns the Medical Breakthroughs?, 39 NEW ENG. L. REv. 665 (2005).

[Vol. 3 9 : 64 7

NEW ENGLAND LA W RE VIE W

660

with hESCR is telling. When President Bush issued h i s pol icy o n h E S C R

on August 9 , 200 1 , my immediate reaction was, "Does he assume these e l l
�
lines are free o f intellectual property entanglements-that they are subject

to free use?" I knew Geron had licenses from the University of W isconsin

and had exercised rights over a lot of the better lines. 60 Sure enough, Geren

was pulled into negotiations with NIH representatives soon after, and the

result was that the lines are accessible via licenses, but on terms that many
researchers find unfavorable.61

What are the costs of a wholly privatized approach in the field of

hESCR? Well, one of the costs is that extensive proprietary interests, an
extension of the source of funding, results in a loss o f derivation c e l l lines

that would potentially make a significant impact in the field. Again, g i ven
the proprietary nature of the research and related information, you also end

up with a loss of public awareness and accountability. Compan ies need

only disclose to the extent necessary to obtain patents, and they usually go

to great extremes to shroud invention with confidentiality and disclosure
agreements and other secrecy measures to maintain patentabi lity and
competitive advantages, and to avoid public relations problems.62 In fact,

the U.S . government is sacrificing a major entitlement to information in
hESCR under standard federal technology transfer law and policy. Even a
small amount of federal funding entitles the U . S . federal government to

receive reports about resulting inventions.63 The government also receives a
non-exclusive right to use inventions that come out of your taxpayer dol lars

in its

60.

own internal research,64

and the U . S .

government engages

in

For more information about these licenses, visit the sites of Geron Corporation, at
http://www .geron.com/,

and

the

Wisconsin

Alumni

Research

Foundation,

at

www.warf.ws.
61.

See O'Connor, supra note 59.

62.

This is the author' s observation based upon years of experience and practice in the
field. See also Rebecca S. Eisenberg, Proprietary Rights and the Norms of Science in
Biotechnology Research, 97 YALE L.J. 1 77 ( 1 987).

63.

See Patent Rights in Inventions Made with Federal Assistance, Pub. L. No. 96-5 1 7, 94

Stat.

3019

(1980) (codified at 35

U.S.C.

§§

200-2 1 2)

(the Bayh-Dole Act);

Technology Innovation Act, Pub. L. No. 96-480, 94 Stat. 23 1 1 ( 1 980) (codified at 1 5
U . S . C . § § 370 1 -37 1 7) (the Stevension-Wydler Technology Innovation Act); Federal
Technology Transfer Act of 1 986, Pub. L. No. 99-502, 1 00 Stat.

1 78 5 ( 1 986)

(codified at 15 U.S.C. §§ 3 7 1 0a-d); Exec. Order No. 1 2 5 9 1 , 52 Fed. Reg. 1 3 ,4 1 4
(Apr. 1 0, 1 987); American Technology Preeminence Act o f 1 99 1 , Pub. L . N o . 1 02245, 1 06 Stat. 7 ( 1 992) (codified in scattered sections of 1 5 U.S.C.); National
Technology Transfer and Advancement Act of 1 995, Pub. L. 1 04- 1 1 3 , 1 1 0 Stat. 7 7 5
( 1 996) (codified i n scattered sections of 1.5 U.S.C.).
64.

See the federal technology transfer policy, which consists of the authority cited supra

note 63.
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significant research in its NIH, 65 FDA, 66 and other laboratories. Keeping
federal taxpayer dollars removed from hESCR means that we as taxpayers
will not have standard entitlement to access inventions in the field of
hESCR unless that access is acquired through government contracts or
other measures. 67
As a point of comparison, consider the United Kingdom's policy on
hESCR. The United Kingdom government has implemented a mandatory
licensing approach for all hESCR in conjunction with endorsing hESCR
68 Consequently,
and making government financial support accessible.
relative to the United States, the U.K. government knows much more about
what hESCR is taking place on its soil even if much of that information
remains proprietary. Moreover, with government support and a favorable
regulatory environment, the United Kingdom has become an attractive
professional destination for those engaged in hESCR, and perhaps investors
also. This leads to yet additional possible U.S. cost consequences of the
Bush policy----consequences that bring us back to basic research. First,
science is global, and, if one believes in market forces, then talent and
money in the field of hESCR are likely to shift to where there is the
greatest opportunity. Second, continued investment of many billions of
dollars in basic research on an annual basis is a reflection of public and
political support of biomedical research. Many human health applications
are particularly attributable to that investment including, at least
historically, significant support for curiosity-driven research. Few private
investors are attracted to curiosity-driven research, so we can assume that
much of that has been driven out of hESCR under the Bush policy.
CONCLUDING THOUGHTS

I would like to close by making a "big picture" conclusion about U.S.
policy and sentiment regarding hESCR. To do so, I ask you to step back to
the announcement in 1998 by Geron Corporation and the University of
Wisconsin that they had successfully isolated human embryonic stem
cells. 69 This was a threshold event for the field which, subsequently, has

65.
66.

67.

For information about the NIH' s laboratories, see http://www.nih.gov.
For information about the FDA's laboratories, see http ://www.fda.gov.
The author's understanding, based upon experience practicing in the field, is that the
United States has not exercised these licenses in a meaningful manner thus far.

68.

Anne McLaren, University of Cambridge, Address
Embryonic Stem Cell Research:

at

Guidelines for Human

A Public Workshop (Oct. 12, 2004) (explaining the

United Kingdom' s approach to hESCR). This address was part of a workshop hosted

69.

by the National Academy of Sciences. See NAT'L ACAD . OF Sc1s., Public Workshop,
supra note 1 3 .
Press Release, Geron Corp., First Derivation of Human Embryonic Stem Cells (Nov.
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70
been advancing in exciting and often unpredictable ways. There certainly
is a before and an after in terms of scientific and pubic debate over hESC R .
Again, this timing was unfortunate from an h E S C R policy
perspective, for it came while the world was absorbing news of Dolly the
sheep and contemplating cloning for human reproduction as a possible
reality. 71 Therapeutic and reproductive cloning have been commingled in
legislative and public debate since, and that debate has been extens ive-in
the media and in federal and state legislatures. 72
In fact, as mentioned earlier, 73 the present state of regulation of AR in
the U.S. makes it impossible to provide assurances to quell ongoing
concern that advances in hESCR will spill over into human reproduction . 7.i
When I teach Bioethics: Law and Policy as I did again thi s semester, as an
assignment, I send my students onto the Internet with the instrnction to
pretend that they are seeking AR services and to bring back a summary of
what they find. It is amazing to shock the "MTV generation," and yet it
happens every time. What they find is aggressive commercialism in the
most fundamental area of medicine from a humanity and society
perspective. Although the United States does have a model compliance
program for AR clinics written up by the Centers for Disease Control and
Prevention (CDC) over a decade ago, no states have adopted it. The United
States depends on a contract between CDC and SART-the professional
society that oversees assisted reproduction-and the voluntary information
that they generate,75 as recognized by the President's Council on
Bioethics. 76 Although I am fairly comfortable with reporting by highly
responsible institutions such as the Harvard-aff iliated Brigham and

70.
71.
72.

73.
74.
75.
76.

5, 1 998), available at http://www .geron.com/pressview.asp?id=5 6 l &print=yes; see
also John Miller, Comment, A Call to Lega l Arms: Bringing Embryon ic Stem Cell
Therapies to Market, 1 3 ALB. L.J. S CI. & TECH. 555 (2003).
See NAT'L ACAD. OF SCIS., Public Workshop, supra note 1 3 .
See supra notes 22-24.

See generally Richard Guerra, Comment, Therapeutic Cloning As Proper Subject
Matter for Patent Eligibility, 43 IDEA 695 (2003); Duane Nash, Recommended
Response for Human Clon ing Patent Applications, 42 IDEA 279 (2002); Peterson,
supra note 26; Suzanne H. Rhodes, Comment, The D ifficulty of Regulating
Reproductive and Therapeutic Cloning: Can the United States Learn Anything from
the Laws of Other Countries?, 2 1 PENN. ST. INT'L L. REV. 3 4 1 (2003 ); David M.
Smolin, Should a Ban on Reproductive Cloning Include a Ban on Cloning for
Purposes of Research or Therapy?, 32 CUMB. L. REV. 487 (2002).
See supra notes 5-8 and accompanying text.
See generally Malinowski, supra note 3.
See supra note 7 and accompanying text.
See PRESIDENT'S COUNCIL, REPRODUCTION AND RESPONSIBILITY surpra
note 3 at 54'
63.
'
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Women's Hospital and Boston 's Children's Hospital, these institutions are
not necessarily representative of the hundreds of for-profit clinics across
the country providing the majority of AR services.
So, at the end of the day, I believe that U.S. policy on hESCR is as
entangled with Dolly and fears about human cloning in reproduction as
therapeutic and reproductive cloning have been coupled in legislative and
public debate. 77 I support hESCR passionately, while also recognizing that
it is asking a lot of the public simply to trust without having some kind of
assurance that the science will not be carried over into human reproduction
and misused. Accordingly, in my opinion, debate over hESCR and U.S.
law-policy should be shifted in the direction of providing that assurance.

77.

See supra note 72 and accompanying text.

